Why Royalty Pharma is betting up to $425m on Neurimmune’s Phase 3 heart drug
Neurimmune sells part of its cliramitug royalty to Royalty Pharma for up to $425 million as the ATTR-CM antibody advances through Phase 3.
Pharma & Biotech